Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Proligo
Boulder, Colorado, USA
- Ownership
- Private
- Development stage
- Other
01
Overview
Proligo was a prominent global supplier of nucleic acid chemistry products and custom oligonucleotide synthesis services. The company specialized in the production of high-quality phosphoramidites, which are essential building blocks for DNA and RNA synthesis. Proligo was particularly recognized for its expertise in RNA synthesis, supporting the emerging field of RNA interference (RNAi) research during the early 2000s. Following its acquisition by Sigma-Aldrich in 2005, its operations were integrated into Sigma-Aldrich's genomics business. The company's legacy and technologies continue to exist as part of the life science portfolio of Merck KGaA.
- Modalities
- Synthetic oligonucleotideRNA therapy
- Industry
- Chemicals & Materials
02
Partnerships
Dharmacon
Beyond the preview
Go deeper on Proligo.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Proligo.